FDA Approves Development of VAR 200 for Treatment of FSGS


FDA approves the development of VAR 200 for the treatment of focal segmental glomerulosclerosis (FSGS) in adults.

Today, Variant Pharmaceuticals, Inc announced that the US Food and Drug Administration (FDA) has approved the development of VAR 200 (2-hydroxypropyl-β-cyclodextrin, or HPβCD) for the treatment of focal segmental glomerulosclerosis (FSGS) in adults.

VAR 200 (2-hydroxypropyl-β-cyclodextrin, or HPβCD) is a phase 2a-ready asset designed to minimize or prevent kidney cell damage and maintain adequate kidney function in patients with FSGS, a rare kidney disease that causes cholesterol and lipids to accumulate in the part of the kidneys that filters waste from the blood.

VAR 200’s intended action is believed to be achieved through the trapping and removal of excess intracellular cholesterol and lipids. Additionally, VAR 200 also has the potential to treat other kidney conditions associated with the damaging effects of intracellular accumulation of cholesterol and lipids, such as Alport syndrome.

Stephen C. Glover, Variant's Co-founder, Chairman, and Chief Executive Officer, stated his excitement for the drug’s development approval. "We are pleased that the FDA concurred with our plans to progress directly into a phase 2a clinical trials in adult patients with FSGS, which will shorten our development time significantly. With no currently available disease-specific treatments approved for FSGS, a high percentage of patients progress to end-stage renal disease within 10 years, requiring dialysis and/or kidney transplant, which has a high recurrence rate."1

In preclinical studies with mice, HPβCD showed promising results. In mouse models of focal segmental glomerulosclerosis FSGS and Alport Syndrome, the progression of kidney disease was prevented, and diabetic kidney disease was prevented or partially prevented in two separate pre-clinical studies.2

"Based on our productive Pre-IND meeting with the FDA, we can confirm that the IND filing will not require any additional nonclinical data before proceeding directly to the phase 2a trial in FSGS adults,” added Glover. “Likewise, we are working with FDA to establish parameters for clinical development of VAR 200 in pediatrics, and we have obtained a clearer understanding of our path forward for longer-term phase 2b/3 trials in adults.”

VAR 200 is also believed to possess the potential to induce remission of proteinuria and delay FSGS progression; this would fulfil an unmet need in this population.

For more data from studies pertaining to the rare disease community, follow Rare Disease Report on Facebook and Twitter.


  1. Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease. Prnewswire.com. https://www.prnewswire.com/news-releases/variant-pharmaceuticals-completes-pre-ind-meeting-with-fda-on-var-200-for-focal-segmental-glomerulosclerosis-fsgs-a-rare-kidney-disease-300629892.html. Accessed April 16, 2018.
  2. About Hydroxypropyl Beta Cyclodextrin.variantpharma.com. https://www.variantpharma.com/pipeline/about-hydroxypropyl-beta-cyclodextrin. Accessed April16, 2018.
Recent Videos
Signs and Symptoms of Connective Tissue Disease
How Gene and Cell Therapy Is Developing in Dermatology
Joyce Teng, MD, PhD, discusses how therapeutic advances in fields like epidermolysis bullosa should progress treatment discourse in other rare dermatoses.
The Prospect of Pz-cel in RDEB Treatment, with Peter Marinkovich, MD
Comparing New Therapies for Dystrophic Epidermolysis Bullosa
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Dunia Hatabah, MD | Image Credit: HCPLive
Ricky Safer: What Clinicians Need to Know About PSC
Ryan T. Fischer, MD: Long-Term Odevixibat Benefit for Alagille Syndrome
Saeed Mohammad, MD: IBAT Inhibitors for Cholestatic Disease
© 2024 MJH Life Sciences

All rights reserved.